Profilaktyka i leczenie powikłań zakrzepowo-zatorowych u pacjentów z chorobą nowotworową Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Jakub Strzelczyk
Patrycja Strzyżewska

Abstrakt

Żylna choroba zakrzepowo-zatorowa (ŻChZZ) jest jednym z częstszych powikłań związanych z chorobą nowotworową. Dotyczy 20% chorych z aktywnym procesem nowotworowym. Szczególnie dużym ryzykiem rozwoju tego powikłania są obarczeni pacjenci z nowotworami hematologicznymi, układu pokarmowego, oddechowego i mózgu. Odpowiednia profilaktyka oparta na indywidualnej ocenie korzyści i zagrożeń może zapobiec ŻChZZ, a w przypadku jej wystąpienia umożliwia zmniejszenie jej następstw i nawrotów. W profilaktyce i terapii przeciwzakrzepowej uwzględnia się heparyny drobnocząsteczkowe (HDCz), heparynę niefrakcjonowaną (HNF) oraz leki doustne – antagonistów witaminy K (AWK).

##plugins.themes.bootstrap3.article.details##

Jak cytować
Strzelczyk , J., & Strzyżewska , P. (2020). Profilaktyka i leczenie powikłań zakrzepowo-zatorowych u pacjentów z chorobą nowotworową . Kardiologia W Praktyce, 14(3-4), 3-14. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1161
Dział
Farmakologia w praktyce kardiologicznej

Bibliografia

1. Mosarla RC, Vaduganathan M, Qamar A et al. Anticoagulation Strategies in Patients With Cancer. JACC Review of The Topic. J Am Coll of Cardiol. 2019; 73(11): 1336-49.
2. Hakoum MB, Kahale LA, Tsolakian IG et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018; 1(1): CD006649.
3. Wojtukiewicz MZ, Sierko E, Tomkowski W et al. Guidelines for the prevention and treatment of venous thromboembolism non-surgically treated cancer patients. Oncol Clin Pract. 2016; 12(3): 67-91.
4. Dallos MC, Eisenberger AB, Bates SE. Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. The Oncologist. 2020; 25(2): 132-9.
5. Pritchard ER, Murillo JR Jr, Putney D et al. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular- weight heparin and vitamin K antagonist in patients with cancer. J Oncol Pharm Practice. 2019; 25(1): 52-9.
6. Zawilska K. Profilaktyka i leczenie żylnych powikłań zakrzepowo-zatorowych u pacjentów z chorobą nowotworową. Hematologia. 2014; 5(3): 228-38.
7. Leizorovicz A, Cohen AT, Turpie AG et al; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110: 874-9.
8. Cohen AT, Davidson BL, Gallus AS et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ. 2006; 332: 325-9.
9. Windyga J. Profilaktyka i leczenie żylnej choroby zakrzepowo-zatorowej u pacjentów chorych na nowotwór złośliwy niepoddawanych operacjom chirurgicznym. Nowotwory J Oncol. 2015; 65: 257-65.
10. Karimi M, Cohan N. Cancer-associated thrombosis. Open Cardiovasc Med J. 2010; 4: 78-82.
11. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004; 24: 1015-22.
12. Kakkar AK, DeRuvo N, Chinswangwatanakul V et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995; 346(8981): 1004-5.
13. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006; 35(1-2): 103-10.
14. Rumbaut RE, Thiagarajan P. Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis. Morgan & Claypool Life Sciences, San Rafael 2010: 35-41.
15. Khorana AA, Liebman HA, White RH et al. The Risk of Venous Thromboembolism in Patients with Cancer. Alexandria, VA: American Society of Clinical Oncology. ASCO Educational Book 2008: 240-8.
16. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160(6): 809-15.
17. Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol Haemost Thromb. 2008; 36(3-4): 131-6.
18. Carrier M, Le Gal G, Wells PS et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008; 149(5): 323-33.
19. Khorana AA. Targeted prophylaxis in cancer: the evidence accumulates. Intern Emerg Med. 2013; 8(3): 187-9.
20. Navi BB, Reiner AS, Kamel H et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017; 70(8): 926-38.
21. Sundbøll J, Veres K, Horváth-Puhó E et al. Risk and prognosis of cancer after lower limb arterial thrombosis. Circulation. 2018; 138(7): 669-77.
22. Brenner B, Bikdeli B, Tzoran I et al; RIETE Investigators. Arterial ischemic events are a major complication in cancer patients with venous thromboembolism. Am J Med. 2018; 131: 1095-103.
23. Grilz E, Königsbrügge O, Posch F et al. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica. 2018; 103: 1549-56.
24. Key NS, Khorana AA, Kuderer NM et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020; 38(5): 496-520.
25. Khorana AA, Soff GA, Kakkar AK et al; CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019; 380: 720-8.
26. Carrier M, Abou-Nassar K, Mallick R et al; AVERT Investigators. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019; 380(8): 711-9.
27. Lee AYY, Levine MN, Baker RI et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146-53.
28. Raskob GE, van Es N, Verhamme P et al; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018; 378(7): 615-24.
29. Young AM, Marshall A, Thirlwall J et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017-23.
30. McBane R II, Wysokinski WE, Le-Rademacher JG et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. Thromb Haemost. 2017; 117(10): 1952-61.
31. Bauersachs R. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. Crit Rev Oncol Hematol. 2018; 132: 169-79.
32. Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019; 30(6): 897-907.
33. Tassinari D, Santelmo C, Scarpi E et al. Controversial issues in thromboprophylaxis with low-molecular weight heparins in palliative care. J Pain Symptom Manage. 2008; 36: e3-e4.
34. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(suppl 2): 152-84.
35. Akl EA, Kahale L, Barba M et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014; 8: CD006650.
36. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107: 14-8.
37. Tomkowski WZ, Dybowska M, Kuca P et al. Effect of a public awareness campaign on the incidence of symptomatic objectively confirmed deep vein thrombosis: A controlled study. J Thromb Haemost. 2012; 10: 2287-90.
38. Hull RD, Pineo GF, Brant RF et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119: 1062-72.
39. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162: 1729-35.
40. Lee AY, Levine MN, Baker RI et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349: 146-53.
41. Deitcher SR, Kessler CM, Merli G et al; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12: 389-96.
42. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000; 18: 3078-83.
43. Francis CW, Kessler CM, Goldhaber SZ et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015; 13: 1028-35.
44. Barbar S, Noventa F, Rossetto V et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010; 8: 2450-7.
45. Elyamany G, Alzahrani AM, Bukhary E. Cancer-Associated Thrombosis: An Overview. Clin Med Insights Oncol. 2014; 8: 129-37.